Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
The live webcast link will be available in the Investors section of Vistagen’s website, under the “Events” tab. A replay of the webcast will be archived on the Company’s website following the presentation.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen’s pherine product candidates are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options, if successfully developed and approved. Vistagen’s most advanced intranasal pherine product candidates are fasedienol in
View source version on businesswire.com: https://www.businesswire.com/news/home/20260514769118/en/
Investor Inquiries:
IR@vistagen.com
Media Inquiries:
media@vistagen.com
Source: Vistagen